Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder
Abstract Individuals with opioid use disorder face barriers accessing first-line pharmacotherapy. Home delivery interventions have been shown to improve medication adherence for other chronic diseases, but the relationship between buprenorphine home delivery and opioid use disorder treatment outcome...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Addiction Science & Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13722-025-00545-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226089404039168 |
|---|---|
| author | Marlene C. Lira Lauren E. Hendy Alisha Liakas Laura Turanchik Clare Pritchard Cynthia Jimes M. Justin Coffey |
| author_facet | Marlene C. Lira Lauren E. Hendy Alisha Liakas Laura Turanchik Clare Pritchard Cynthia Jimes M. Justin Coffey |
| author_sort | Marlene C. Lira |
| collection | DOAJ |
| description | Abstract Individuals with opioid use disorder face barriers accessing first-line pharmacotherapy. Home delivery interventions have been shown to improve medication adherence for other chronic diseases, but the relationship between buprenorphine home delivery and opioid use disorder treatment outcomes has not been assessed. We evaluated the association between medication home delivery and retention in treatment in a feasibility study of adults who initiated telemedicine treatment for opioid use disorder and received one or more prescriptions. We described the characteristics of patients and estimated the odds of attending a telemedicine visit three and six months after enrollment as a function of home delivery use using logistic regression. The sample consisted of 337 adults with the following characteristics: mean age 40.8 years (SD 10.1), 51.0% male, and 70.9% commercially insured. In the first 30 days of treatment 6.8% (n = 23) of patients used home delivery. At three months, the percentages of individuals retained among those with and without home delivery were 82.6% and 58.9%, respectively (odds ratio [OR]: 3.31, 95% confidence interval [CI]: 1.10–9.96). At six months, the percentages of individuals retained among those with and without home delivery were 78.6% and 45.5%, respectively (OR: 4.39, 95% CI: 1.19–16.25, n = 203). Although uptake of medication delivery through the pharmacy partner was low within this sample of patients receiving treatment for opioid use disorder, its use was associated with increased retention in care at three and six months. Given the small sample size, low uptake, and limited statistical power, additional research is warranted. |
| format | Article |
| id | doaj-art-c40ae2954b914dfc8681ab2c213bed3c |
| institution | Kabale University |
| issn | 1940-0640 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Addiction Science & Clinical Practice |
| spelling | doaj-art-c40ae2954b914dfc8681ab2c213bed3c2025-08-24T11:42:45ZengBMCAddiction Science & Clinical Practice1940-06402025-02-012011510.1186/s13722-025-00545-2Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorderMarlene C. Lira0Lauren E. Hendy1Alisha Liakas2Laura Turanchik3Clare Pritchard4Cynthia Jimes5M. Justin Coffey6Workit HealthWorkit HealthWorkit HealthWorkit HealthWorkit HealthWorkit HealthWorkit HealthAbstract Individuals with opioid use disorder face barriers accessing first-line pharmacotherapy. Home delivery interventions have been shown to improve medication adherence for other chronic diseases, but the relationship between buprenorphine home delivery and opioid use disorder treatment outcomes has not been assessed. We evaluated the association between medication home delivery and retention in treatment in a feasibility study of adults who initiated telemedicine treatment for opioid use disorder and received one or more prescriptions. We described the characteristics of patients and estimated the odds of attending a telemedicine visit three and six months after enrollment as a function of home delivery use using logistic regression. The sample consisted of 337 adults with the following characteristics: mean age 40.8 years (SD 10.1), 51.0% male, and 70.9% commercially insured. In the first 30 days of treatment 6.8% (n = 23) of patients used home delivery. At three months, the percentages of individuals retained among those with and without home delivery were 82.6% and 58.9%, respectively (odds ratio [OR]: 3.31, 95% confidence interval [CI]: 1.10–9.96). At six months, the percentages of individuals retained among those with and without home delivery were 78.6% and 45.5%, respectively (OR: 4.39, 95% CI: 1.19–16.25, n = 203). Although uptake of medication delivery through the pharmacy partner was low within this sample of patients receiving treatment for opioid use disorder, its use was associated with increased retention in care at three and six months. Given the small sample size, low uptake, and limited statistical power, additional research is warranted.https://doi.org/10.1186/s13722-025-00545-2Opioid use disorderTelemedicineBuprenorphineMedication deliveryHome deliveryPharmacy barriers |
| spellingShingle | Marlene C. Lira Lauren E. Hendy Alisha Liakas Laura Turanchik Clare Pritchard Cynthia Jimes M. Justin Coffey Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder Addiction Science & Clinical Practice Opioid use disorder Telemedicine Buprenorphine Medication delivery Home delivery Pharmacy barriers |
| title | Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| title_full | Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| title_fullStr | Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| title_full_unstemmed | Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| title_short | Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| title_sort | early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder |
| topic | Opioid use disorder Telemedicine Buprenorphine Medication delivery Home delivery Pharmacy barriers |
| url | https://doi.org/10.1186/s13722-025-00545-2 |
| work_keys_str_mv | AT marleneclira earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT laurenehendy earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT alishaliakas earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT lauraturanchik earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT clarepritchard earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT cynthiajimes earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder AT mjustincoffey earlyfindingsonhomedeliveryofbuprenorphineandretentionintreatmentforopioidusedisorder |